Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Greed Is Good who wrote (184)	12/11/1997 5:05:00 AM
From: Harry D. Kramer	Read Replies (1) \| Respond to of 1510

The company is called CEL-SCI. The symbol is HIV and the stock is listed on AMEX. It is one of the more interesting biotechs working in the field of HIV treatment and prevention. It is definitely a company you have to follow on your radar screen if you are long IMNR. CEL-SCI is developing a HIV product called HGP-30. They have clinical trials with this product as a therapeutic and as a prophylactic vaccine. They are at least two years behind IMNR in the therapeutic area, but the product in the end may be the better one. But too soon to tell. IMNR, by the way, is just going the therapeutic way, whereas CEL-SCI is going after therapy and prevention. I haven't seen CNBC, but I am sure this is the company they were talking about. They presented data from studies with HGP-30 in SCID mice yesterday. For details see: biz.yahoo.com IMNR has had a nice run in the last two weeks, so give it a chance to rest. The stock has gone up more than 50% in less than 4 months, don't forget that. Can I call you Greed? :-) Take care, Harry

To: Greed Is Good who wrote (184)	12/11/1997 2:25:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

anyone have any details on the form 4 filed 2 days ago? also i signed up for wall street voice but they would not give those details are there any better sites for the inside trades? and also mark can immune possibly sell 3 million more shares on the market of the 6 million left or another private offering to raise enough capital? Iam real hazy about all these influences on market price, but it seems as they approach these new highs the sec forms come rolling out. thanks ar.